Side-by-side research comparison of Ipamorelin and MK-677 across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. No direct head-to-head trials in our corpus — this comparison synthesizes indirect evidence across 45 Ipamorelin studies and 96 MK-677 studies.
| Ipamorelin | MK-677 | |
|---|---|---|
| Drug class | ghrh secretagogue, ghrelin mimetic | n/a |
| Studies in corpus | 45 | 96 |
| Highest evidence tier | rct | rct |
| Evidence tier mix | other · 12 preclinical animal · 22 rct · 4 in vitro · 5 review · 1 | case report · 4 rct · 10 other · 20 preclinical animal · 29 in vitro · 15 review · 15 |
| Studies with explicit sample size | 3 | 2 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Ipamorelin and MK-677 batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 1804 Ipamorelin batches across 638 manufacturers, 99.52% avg purity.
We tested 58 MK-677 batches across 29 manufacturers, 98.55% avg purity.
We hold deeper lab coverage on Ipamorelin (1804 batches tested). Ipamorelin edges ahead on average measured purity (99.52% vs 98.55%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Looking for vendor-level purity, endotoxin, and HPLC data on Ipamorelin or MK-677? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.